Wall Street brokerages expect that CytRx Co. (NASDAQ:CYTR) will announce earnings of ($0.07) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for CytRx’s earnings. CytRx reported earnings of ($0.16) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 56.3%. The company is scheduled to report its next earnings results on Monday, March 18th.
On average, analysts expect that CytRx will report full-year earnings of ($0.41) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.24) per share. Zacks’ EPS calculations are an average based on a survey of analysts that follow CytRx.
CytRx (NASDAQ:CYTR) last issued its earnings results on Friday, November 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The company had revenue of $0.25 million during the quarter.
A number of brokerages recently commented on CYTR. Zacks Investment Research raised CytRx from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, November 7th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of CytRx in a research report on Monday, November 5th. Finally, ValuEngine raised CytRx from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.
A hedge fund recently raised its stake in CytRx stock. Virtu Financial LLC lifted its stake in shares of CytRx Co. (NASDAQ:CYTR) by 327.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 90,678 shares of the biotechnology company’s stock after acquiring an additional 69,444 shares during the quarter. Virtu Financial LLC owned 0.27% of CytRx worth $40,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.80% of the company’s stock.
Shares of CYTR remained flat at $$0.61 during mid-day trading on Tuesday. The stock had a trading volume of 127,893 shares, compared to its average volume of 174,418. CytRx has a 52-week low of $0.33 and a 52-week high of $2.35.
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies.
Featured Story: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.